K_i-67/MIB-1 and Recurrence in Pituitary Adenoma

Abstract

Objectives K_i-67/MIB-1 is a marker of cellular proliferation used as a pathological parameter in the clinical assessment of pituitary adenomas, where its expression has shown utility in predicting the invasiveness of these tumors. However, studies have shown variable results when using K_i-67/MIB-1 association with recurrence. The purpose of this study is to determine if a high K_i-67/MIB-1 labeling index (LI) is predictive of recurrence in pituitary adenomas.

Methods A retrospective chart review was performed for patients undergoing pituitary adenoma resection with at least 1 year of follow-up. Additionally, systematic data searches were performed and included studies that correlated recurrence rate to K_i-67/MIB-1 LI. Our institutional data were included in a synthesis with previously published data.

Results Our institutional review included 79 patients with a recurrence rate of 26.6%. We found that 8.8% of our patients had a high K_i-67/MIB-1 LI (>3%); however, high K_i-67/MIB-1 was not associated with recurrence. The systematic review identified 244 articles and 49 full-text articles that were assessed for eligibility. Quantitative analysis was performed on 30 articles including our institutional data and 18 studies reported recurrence by level of K_i-67/MIB-1 LI. Among studies that compared K_i-67/MIB-1 ≥3 vs. <3%, 10 studies reported odds ratios (OR) greater than 1 of which 6 were statistically significant. A high K_i-67/MIB-1 had higher odds of recurrence via the pooled odds ratio (OR = 4.15, 95% confidence interval [CI]: 2.31–7.42).

Conclusion This systematic review suggests that a high K_i-67/MIB-1 should prompt an increased duration of follow-up due to the higher odds of recurrence of pituitary adenoma.

Keywords

pituitary adenoma - K_i-67 - MIB-1 - recurrence

Publikationsverlauf

Eingereicht: 05. April 2021

Angenommen: 11. August 2021

Artikel online veröffentlicht:
21. September 2021

• References

• 1 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182 (03) 311-322
• 2 Karamitopoulou E, Perentes E, Tolnay M, Probst A. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998; 29 (02) 140-145
• 3 Hu H-Y, Liu H, Zhang J-W, Hu K, Lin Y. Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepatogastroenterology 2012; 59 (120) 2640-2643
• 4 Nabi U, Nagi AH, Sami W. Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J Ayub Med Coll Abbottabad 2008; 20 (04) 44-48
• 5 Morimoto R, Satoh F, Murakami O. et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008; 55 (01) 49-55
• 6 Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984; 2 (04) 365-371
• 7 Thapar K, Kovacs K, Scheithauer BW. et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38 (01) 99-106 , discussion 106–107
• 8 Raverot G, Vasiljevic A, Jouanneau E. Prognostic factors of regrowth in nonfunctioning pituitary tumors. Pituitary 2018; 21 (02) 176-182
• 9 Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 2012; 15 (01) 71-83
• 10 Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new?. Acta Neuropathol 2006; 111 (01) 1-7
• 11 Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003; 73 (09) 712-716
• 12 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
• 13 Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T. MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 1997; 139 (05) 426-431 , discussion 431–432
• 14 Nakabayashi H, Sunada I, Hara M. Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 2001; 49 (09) 1193-1194
• 15 Espay AJ, Azzarelli B, Williams LS, Bodensteiner JB. Recurrence in pituitary adenomas in childhood and adolescence. J Child Neurol 2001; 16 (05) 364-367
• 16 Hentschel SJ, McCutcheon E, Moore W, Durity FA. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 2003; 30 (03) 215-219
• 17 Filippella M, Galland F, Kujas M. et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006; 65 (04) 536-543
• 18 Dubois S, Guyétant S, Menei P. et al. Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 2007; 157 (02) 141-147
• 19 Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM. Non-functioning pituitary adenoma: immunohistochemical analysis of 85 cases. Folia Neuropathol 2007; 45 (02) 72-77
• 20 Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 2008; 39 (05) 758-766
• 21 Noh T-W, Jeong HJ, Lee M-K, Kim TS, Kim SH, Lee EJ. Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2009; 94 (11) 4406-4413
• 22 Widhalm G, Wolfsberger S, Preusser M. et al. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 2009; 111 (03) 563-571
• 23 Matsuyama J. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir (Tokyo) 2012; 52 (08) 563-569
• 24 Righi A, Agati P, Sisto A. et al. A classification tree approach for pituitary adenomas. Hum Pathol 2012; 43 (10) 1627-1637
• 25 Magagna-Poveda A, Leske H, Schmid C, Bernays R, Rushing EJ. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications. Swiss Med Wkly 2013; 143: w13895
• 26 Righi A, Morandi L, Leonardi E. et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol 2013; 44 (11) 2400-2409
• 27 Sánchez-Tejada L, Sánchez-Ortiga R, Moreno-Pérez O. et al. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Endocrinol Nutr 2013; 60 (07) 358-367
• 28 Trouillas J, Roy P, Sturm N. et al; members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013; 126 (01) 123-135
• 29 Chiloiro S, Bianchi A, Doglietto F. et al. Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 2014; 17 (03) 267-276
• 30 Šteňo A, Bocko J, Rychlý B. et al. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth. Acta Neurochir (Wien) 2014; 156 (03) 451-461 , discussion 461
• 31 Landeiro JA, Fonseca EO, Monnerat ALC, Taboada GF, Cabral GAPS, Antunes F. Nonfunctioning giant pituitary adenomas: invasiveness and recurrence. Surg Neurol Int 2015; 6: 179
• 32 Kim JS, Lee YS, Jung MJ, Hong YK. The predictive value of pathologic features in pituitary adenoma and correlation with pituitary adenoma recurrence. J Pathol Transl Med 2016; 50 (06) 419-425
• 33 Song Y-J, Chen M-T, Lian W. et al. Surgical treatment for male prolactinoma: a retrospective study of 184 cases. Medicine (Baltimore) 2017; 96 (02) e5833
• 34 Sadeghipour A, Mahouzi L, Salem MM. et al. Ki67 labeling correlated with invasion but not with recurrence. Appl Immunohistochem Mol Morphol 2017; 25 (05) 341-345
• 35 Matoušek P, Buzrla P, Reguli Š, Krajča J, Dvořáčková J, Lipina R. Factors that predict the growth of residual nonfunctional pituitary adenomas: correlations between relapse and cell cycle markers. BioMed Res Int 2018; 2018: 1876290
• 36 Antunes X, Ventura N, Camilo GB. et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 2018; 60 (03) 415-422
• 37 Lv L, Hu Y, Yin S. et al. Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas. Clin Neurol Neurosurg 2018; 167: 93-98
• 38 Liu X, Feng M, Zhang Y. et al. Expression of matrix metalloproteinase-9, pituitary tumor transforming gene, high mobility group A 2, and Ki-67 in adrenocorticotropic hormone-secreting pituitary tumors and their association with tumor recurrence. World Neurosurg 2018; 113: e213-e221
• 39 Hasanov R, Aydoğan Bİ, Kiremitçi S, Erden E, Güllü S. The prognostic roles of the Ki-67 proliferation index, P53 expression, mitotic index, and radiological tumor invasion in pituitary adenomas. Endocr Pathol 2019; 30 (01) 49-55
• 40 Asioli S, Righi A, Iommi M. et al. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 2019; 180 (02) 127-134
• 41 Nikitin PV, Ryzhova MV, Shishkina LV, Shugay SV, Zubova IV. Study of simple immunohistochemical cytocolorimetric assay application for more accurate assessment of prognosis in patients with pituitary adenomas. World Neurosurg 2019; 122: e1047-e1051
• 42 Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37 (01) 151-171 , xi
• 43 Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27 (05) 485-534
• 44 McCoul ED, Bedrosian JC, Akselrod O, Anand VK, Schwartz TH. Preservation of multidimensional quality of life after endoscopic pituitary adenoma resection. J Neurosurg 2015; 123 (03) 813-820
• 45 Bhenswala PN, Schlosser RJ, Nguyen SA, Munawar S, Rowan NR. Sinonasal quality-of-life outcomes after endoscopic endonasal skull base surgery. Int Forum Allergy Rhinol 2019; 9 (10) 1105-1118
• 46 Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997; 32 (04) 410-415
• 47 Bettencourt M-C, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156 (03) 1064-1068
• 48 Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 1995; 19 (05) 446-450
• 49 Micko ASG, Wöhrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015; 122 (04) 803-811
• 50 Gerges MM, Rumalla K, Godil SS. et al. Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas. J Neurosurg 2020; x: 1-12
• 51 Dallapiazza RF, Grober Y, Starke RM, Laws Jr. ER, Jane Jr JA. Long-term results of endonasal endoscopic transsphenoidal resection of nonfunctioning pituitary macroadenomas. Neurosurgery 2015; 76 (01) 42-52 , discussion 52–53
• 52 Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf) 2003; 58 (06) 763-769
• 53 Lv L, Yin S, Zhou P. et al. Clinical and pathologic characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. World Neurosurg 2018; 118: e428-e435
• 54 Soto-Ares G, Cortet-Rudelli C, Assaker R. et al. MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur J Endocrinol 2002; 146 (02) 179-186
• 55 Park P, Chandler WF, Barkan AL. et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 2004; 55 (01) 100-106 , discussion 106–107
• 56 Chang EF, Zada G, Kim S. et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 2008; 108 (04) 736-745
• 57 Chen Y, Wang CD, Su ZP. et al. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 2012; 96 (04) 333-342
• 58 Brochier S, Galland F, Kujas M. et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 2010; 163 (02) 193-200
• 59 Ziu M, Dunn IF, Hess C. et al. Congress of neurological surgeons systematic review and evidence-based guideline on posttreatment follow-up evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 2016; 79 (04) E541-E543